Atherosclerotic cardiovascular disease (ASCVD) is caused by plaque buildup in arterial walls. Clinical / established ASCVD consists of acute coronary syndromes, a history of myocardial infarction (…
Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity to…
In the last decade, the biosimilar therapy market has been growing, led mainly by two therapeutic areas: immunology and oncology. It now continues to expand into new fields. To enhance this growth…
In 2019, Amgen / Allergan's trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…
asdfasdf
The biosimilar / follow-on insulin sector of the diabetes therapy market is evolving. Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine…
For neurologists, established molecules like leveteriacetam, lamotrigine, and carbamazepine remain the first choice of treatment for epilepsy; however, the new entrants in the market are evoloving…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…
Hormone receptor (HR)-positive / HER2-negative breast cancer has the highest incidence of all breast cancer subtypes. Treatment decisions are influenced by the stage of the disease, the patient’…
Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative market for pharmacotherapies owing to the lack of approved agents and the disease’s relatively high prevalence…
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and accounts for about 20% of cases of acute leukemia in adults. Chemotherapy has remained the backbone of first-line…
The current treatment armamentarium for non-small-cell lung cancer (NSCLC) is dominated by biomarker-driven therapies and immune checkpoint inhibitors. Therapeutic options in this indication have…
The treatment of ovarian cancer has historically been dominated by chemotherapy, but angiogenesis and PARP inhibitors are optimizing treatment options. The regulatory approvals of AstraZeneca /…
Opioid addiction is a chronic disease, generally driven by a strong and irresistible urge or craving for the intake of opioid drugs and an inability to stop despite negative consequences to health…
Disease stage, primary tumor resectability, and BRAF mutation status are key parameters influencing the treatment paradigm of malignant melanoma patients. BRAF/MEK inhibitor combination regimens,…